This phase II study is evaluating the effect of a targeted therapy (alectinib) in people with newly diagnosed metastatic non-squamous small cell lung cancer (NSCLC) or people with advanced solid cancers with ALK gene alterations.
This trial is treating patients with newly diagnosed metastatic non-squamous non-small cell lung cancer, and advanced or metastatic solid cancers with ALK gene alteration.
This is a systemic therapy trial.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
- You have been diagnosed with cancer, but have not received any treatment.
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- Your cancer has not spread to other parts of the body.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
- CTC 0141 – ADDENDUM 14; U1111-1263-7887
A Single arm, open label, phase II trial of tumour response to alectinib in patients with advanced tumours harbouring ALK gene alterations detected by comprehensive genomic profiling
OMICO - Outsmarting Cancer Together
Other Non-Commercial Sponsor
University of Sydney
This is a substudy of the Cancer Molecular Screening and Therapeutics (MoST) Program (ACTRN12616000908437). Eligible participants will receive continuous alectinib (600mg oral capsules) twice a day until disease progression, participant withdrawal or unacceptable toxicity.
Recruiting Hospitals Read More